Lexaria Bioscience (LEXX) Return on Capital Employed (2018 - 2026)

Lexaria Bioscience has disclosed Return on Capital Employed across 9 years of filings, most recently posting 156.33% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 156.33%, down 2969.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 156.33% (down 2969.0% YoY), and the FY2025 annual result was 236.29%, down 11831.0% from the prior year.
• Return on Capital Employed came in at 156.33% for Q1 2026 at Lexaria Bioscience, up from 294.38% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 2347.27% in Q2 2023 to a low of 32485.66% in Q1 2024.
• The 5-year median for Return on Capital Employed is 156.33% (2026), against an average of 1987.14%.
• Across the five-year window, Return on Capital Employed slumped 3144631 bps in 2024 and jumped 3235902 bps in 2025, its largest moves.
• Lexaria Bioscience's Return on Capital Employed stood at 170.82% in 2022, then sank by 136 bps to 402.87% in 2023, then surged by 80 bps to 80.87% in 2024, then plunged by 264 bps to 294.38% in 2025, then soared by 47 bps to 156.33% in 2026.
• The last three Return on Capital Employed figures came in at 156.33% (Q1 2026), 294.38% (Q4 2025), and 299.66% (Q3 2025), per Business Quant data.